Anxiety Disorder

Researchers are evaluating erectile function changes in male patients who undergo percutaneous coronary intervention (PCI) for either a heart attack or stable angina. The study aims to understand how myocardial infarction affects erectile function over time and to explore whether erectile dysfunction can predict future cardiac events. This observational study compares erectile function between patients with myocardial infarction and those with stable angina using standardized questionnaires. Participants are grouped into two sets: those treated with PCI after a heart attack and those treated due to stable angina. Erectile function is assessed at baseline (after recovery from PCI), and at 3 and 6 months post-procedure using the International Index of Erectile Function (IIEF) questionnaire. Additional assessments include the Beck Depression Inventory and Fear of Cardiac Recurrence and Progression Scale. Researchers also collect clinical data such as cardiac vessel scores, ejection fraction, testosterone levels, body measurements, medication use, and the intervention method. During the study, male participants aged 30 to 75 will complete face-to-face interviews and questionnaires at specified intervals: baseline, 3 months, and 6 months after PCI. The study measures changes in erectile function scores over time and examines associations with cardiac health, depression, and anxiety symptoms. Safety and participation are monitored throughout the follow-up period. The total duration of involvement is up to 6 months, with evaluations focusing on erectile function and related health parameters.

This observational study investigates the relationship between tongue color features and anxiety-depression levels in patients receiving acupuncture. Researchers aim to see if tongue photographs taken with standard smartphone cameras can predict scores on the Montgomery-Åsberg Depression Rating Scale (MADRS), which measures anxiety and depression severity. The goal is to explore a new, non-invasive way to assess mental health using machine learning analysis. Participants will have their tongues photographed using an iPhone under standardized conditions to ensure consistent lighting and positioning. They will also complete the MADRS questionnaire during a routine acupuncture visit. No treatments or invasive procedures will be changed or added during the study. The collected data will be analyzed with machine learning methods to identify patterns between tongue color and anxiety-depression scores. During the study, participants only need to attend one visit where tongue images and questionnaire responses are collected. Researchers will measure the correlation between tongue color metrics and MADRS scores at this single timepoint. There are no additional treatments or follow-ups required. The study uses everyday technology to make this assessment easy and accessible in clinical settings, aiming to improve early detection and monitoring of anxiety and depression.

This research aims to evaluate how a structured productivity training program affects nurses' perceived job stress and their attitudes toward productivity. The study is designed as a randomized controlled experimental trial with assessments before the training, immediately after, and three months later. Researchers want to see if nurses who receive the training report lower stress and better productivity attitudes compared to those who do not. The study involves two groups: an experimental group that receives a three-week productivity training totaling 20 hours, and a control group that receives no training during the same period. The training covers nursing productivity concepts, time and stress management, teamwork, leadership, digital tools, and coping with job stress. Various teaching methods like lectures, case studies, simulations, and group work are used to improve cognitive, emotional, and practical skills. Participants will complete assessments using the Nurses' Attitudes Toward Productivity Scale and the Perceived Job Stress Scale at three time points: before training, right after the training, and three months later. The control group also completes these assessments without receiving training during the study but will get access to the training materials afterward. The total study duration includes the training period plus follow-up assessments to monitor lasting effects.

This research aims to evaluate a 5-session cognitive behavioral program called 1MoreStep, designed for Black women living with HIV who have experienced intimate partner violence in the past two years. The study focuses on teaching skills to access personal and external strengths, safety strategies, knowledge about HIV care and stigma, communication skills to handle stigma, and addressing barriers to HIV care. It also examines the program's acceptability and feasibility among participants. Participants are randomly assigned to either the 1MoreStep intervention or an equal attention control group. The intervention includes seven group sessions and one individual session held weekly, led by experienced facilitators from the Black community. Sessions cover topics such as safety planning, HIV care engagement, stigma communication, and goal setting using cognitive behavioral skills. The control group attends weekly support group sessions that cover general health topics important to Black women living with HIV but not directly related to the intervention's goals. Throughout the study, participants complete assessments at baseline, 3 months, and 6 months to measure changes in safety strategies and HIV care engagement. Measures include surveys, medical record reviews, and interviews to evaluate treatment acceptance, session attendance, and participant experiences. The study spans approximately 6 months post-baseline, with follow-up surveys and qualitative interviews to explore program fit and barriers to participation.

Researchers are investigating how the antidepressant citalopram affects the brain's response to emotional information, focusing on the amygdala, a key brain area involved in depression. This study explores how different parts of the amygdala react to positive and negative emotional stimuli, using advanced brain scanning technology to understand the underlying brain mechanisms. Participants will receive a single oral dose of either 20 mg citalopram or a placebo in a randomized, double-blind design. After dosing, participants will undergo high-strength 7T fMRI brain scans while viewing emotional faces. This precise imaging allows researchers to observe how citalopram influences specific subfields of the amygdala during emotional processing. Participants will be screened for medical and psychiatric health before joining. During the study, brain activity and behavioral responses such as accuracy and reaction time during a gender discrimination task will be measured about three hours after dosing. The study includes safety monitoring and lasts for a few hours on the study day, focusing on neural and behavioral outcomes related to emotional processing.

Researchers are evaluating a community health worker-delivered mental health counseling intervention delivered remotely via a mobile health app to reduce anxiety and depression among people living with HIV in Florida. This pilot randomized controlled trial aims to assess the preliminary effectiveness of this adapted positive affect counseling approach compared to the standard version of the app and usual mental health care. The study is sponsored by the University of Florida and focuses on improving mental health outcomes in this population. Participants will be randomly assigned to one of two groups. The intervention group will receive approximately five weekly 60-minute individual counseling sessions via secure video calls through a modified PositiveLinks app that includes enhanced mental health resources. If symptoms do not improve, participants may be referred to a licensed mental health professional. The control group will use the standard PositiveLinks app, which provides feedback on anxiety and depression symptoms and a list of local mental health resources without counseling. During the study, data will be collected from participants' electronic medical records and the app for about six months after enrollment. Researchers will measure changes in anxiety and depression levels at three months as primary outcomes. Participants will provide informed consent before joining, and there is no masking or blinding in the trial. The study will monitor mental health symptoms and the use of counseling through app data and medical records to evaluate the intervention's preliminary effectiveness.

Women who have experienced interpersonal violence often face a higher risk of developing post-traumatic stress disorder (PTSD). In France, female victims can request a medico-legal examination at a clinical forensic medicine unit, which also offers initial psychological assessment. However, many women do not attend follow-up appointments. This research is a prospective, multicenter, open-label, randomized controlled trial aiming to evaluate the effectiveness of a case management algorithm that uses early phone contact to improve clinical outcomes after such consultations for female victims of violence. Participants are divided into two groups. The experimental group, called VIGITRAUMA, will receive a phone call three weeks after their consultation, with a second call if needed. If contact is not made after the second call, a postcard will be sent. The control group will receive the usual follow-up care without this additional phone contact. The study is conducted by the University Hospital, Lille. Participants will be assessed through phone calls at 3, 6, and 12 months after their consultation to monitor clinical outcomes. Researchers will measure PTSD symptom severity, general psychopathology, somatic symptoms, medical costs, judicial outcomes, suicidal thoughts, and suicide attempts. The study aims to track these outcomes over a full year to understand the impact of the case management algorithm compared to standard care.

Researchers are conducting the GENESIS clinical study to map the HLA genomic region in the Greek population and explore its possible links with various underlying diseases. This non-interventional, multicenter study aims to provide a pilot map of genetic variation in HLA that may be useful in medical research and clinical applications related to selected diseases. The study plans to include 12,000 participants over a total duration of 36 months. Each participant will attend one visit at a participating site during which they will provide demographic data, lifestyle information such as smoking and alcohol use, blood pressure measurements, details on diagnosed diseases and treatments, and recent laboratory test results if available. Buccal swab samples will be collected from each participant to extract DNA for HLA genotyping analysis. Selected samples will undergo further whole genome sequencing to investigate associations with autoimmune diseases. Participants will receive a personalized ancestry report after analysis completion. During the study visit, data collection includes demographic and health information, as well as laboratory and clinical test results from the past year. The genetic material from buccal swabs will be stored and processed for genetic analysis. Researchers will measure allele frequency of HLA alleles in the Greek population and assess the prevalence and risk associations of selected HLA-related diseases. The study's total duration is 36 months with results available at the end of this period.

This research aims to evaluate interventions to support family members who act as surrogate decision makers for critically ill patients in Intensive Care Units (ICUs). These surrogates often face intense grief and stress that can affect their mental health and the quality of decisions made for their loved ones near end-of-life. The study focuses on reducing symptoms of prolonged grief disorder (PGD), post-traumatic stress disorder (PTSD), and related emotional challenges through a psychological intervention called EMPOWER. The study compares two approaches: the EMPOWER intervention, which is a brief, cognitive-behavioral and acceptance-based treatment delivered by trained mental health professionals, and a Supportive Conversation (SC) that provides empathetic support without specific skill-building. EMPOWER includes six 15-minute modules and two booster phone sessions, totaling about 90 minutes plus follow-ups, while the Supportive Conversation matches this time with supportive interaction and follow-up calls. Participants are assessed up to four times before and after the intervention within three months. Participants, who are surrogate decision makers of ICU patients near end-of-life, will complete assessments on grief, PTSD, depression, regret, anxiety, and distress before the intervention, immediately after, and at 3 and 12 months follow-up. The study also includes interviews with some participants to better understand the intervention's effects and contextual factors during the COVID-19 pandemic. The primary outcomes focus on changes in grief and PTSD symptoms over twelve months, with safety and mental health monitored throughout the study period.

This trial investigates the effects of Fasedienol Nasal Spray in adults aged 18 to 65 with Social Anxiety Disorder (SAD) triggered by a public speaking challenge. It is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study aiming to assess the safety, tolerability, and effectiveness of repeated intranasal doses of Fasedienol to relieve acute anxiety symptoms in a clinical setting. Participants will be randomly assigned to one of three groups: one receiving a dose of Fasedienol followed by a placebo spray, another receiving two doses of Fasedienol, and a third receiving two doses of placebo spray. The sprays are administered twenty minutes before the public speaking challenge, with ten minutes between doses. Those who complete this phase may enter an open-label extension where they can use Fasedienol as needed, up to six times daily for up to 12 months to assess longer-term safety and tolerability. During the study, participants will undergo assessments including the Subjective Units of Distress Scale (SUDS), Clinical Global Impression of Improvement (CGI-I), and Patient Global Impression of Change (PGI-C) over seven days. Researchers will monitor symptoms of anxiety, safety, and tolerability through clinical evaluations. The total participation timeline includes initial treatment and possible extended use with ongoing observation until the study ends in December 2026.